Biotron Limited (ASX:BIT)
Australia · Delayed Price · Currency is AUD 0.0040
+0.0010 (33.33%)
Jan 30, 2026, 2:34 PM AEST
Biotron Company Description
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
The company’s lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections.
The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited
| Country | Australia |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Michelle Miller |
Contact Details
Address: 66 Hunter Street Sydney, NSW 2000 Australia | |
| Phone | 61 2 9300 3344 |
| Website | biotron.com.au |
Stock Details
| Ticker Symbol | BIT |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000BIT4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. | MD and Executive Director |
| Marcelo Mora ACIS, B.Bus Aasa | Company Secretary |